MET and non-small cell lung carcinoma: NSCLC harboring METex14 skipping alterations in about 8–15% also harbor concomitant MET amplifications [4]; however, MET amplification as a primary driver also occurs as a distinct oncogenic event in the absence of METex14 skipping.